These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 9767282)

  • 1. Investigation on a novel and specific leukotriene B4 receptor antagonist in the treatment of stable plaque psoriasis.
    Van Pelt JP; De Jong EM; Seijger MM; Van Hooijdonk CA; De Bakker ES; Van Vlijmen IM; Parker GL; Van Erp PE; Van De Kerkhof PC
    Br J Dermatol; 1998 Sep; 139(3):396-402. PubMed ID: 9767282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological effects of a specific leukotriene B(4) receptor antagonist (VML 295) on blood leukocytes, cutaneous inflammation and epidermal proliferation.
    Seegers BA; Andriessen MP; van Hooijdonk CA; de Bakker ES; van Vlijmen-Willems IM; Parker GL; van Erp PE; van de Kerkhof PC
    Skin Pharmacol Appl Skin Physiol; 2000; 13(2):75-85. PubMed ID: 10754455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The regulation of CD11b integrin levels on human blood leukocytes and leukotriene B4-stimulated skin by a specific leukotriene B4 receptor antagonist (LY293111).
    van Pelt JP; de Jong EM; van Erp PE; Mitchell MI; Marder P; Spaethe SM; van Hooijdonk CA; Kuijpers AL; van de Kerkhof PC
    Biochem Pharmacol; 1997 Apr; 53(7):1005-12. PubMed ID: 9174114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of LY293111Na, a leukotriene B4 receptor antagonist, on the pulmonary neutrophilia and CD11b expression caused by inhalation of a leukotriene B4 aerosol in rhesus monkeys.
    Allen DL; Hoffman WP; Marder P; Matchett MR; Leiter PA; Abbott DL; Wolff RK
    J Pharmacol Exp Ther; 1996 Apr; 277(1):341-9. PubMed ID: 8613940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VML 295 (LY-293111), a novel LTB4 antagonist, is not effective in the prevention of relapse in psoriasis.
    Mommers JM; Van Rossum MM; Kooijmans-Otero ME; Parker GL; van de Kerkhof PC
    Br J Dermatol; 2000 Feb; 142(2):259-66. PubMed ID: 10730758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of ex vivo neutrophil activation by oral LY293111, a novel leukotriene B4 receptor antagonist.
    Marder P; Spaethe SM; Froelich LL; Cerimele BJ; Petersen BH; Tanner T; Lucas RA
    Br J Clin Pharmacol; 1996 Oct; 42(4):457-64. PubMed ID: 8904617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical treatment of psoriatic plaques with 1 alpha, 24 dihydroxyvitamin D3: a multiparameter flow cytometrical analysis of epidermal growth, differentiation and inflammation.
    Glade CP; van Erp PE; van Hooijdonk CA; Elbers ME; van de Kerkhof PC
    Acta Derm Venereol; 1995 Sep; 75(5):381-5. PubMed ID: 8615058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of systemic treatment with liarozole on cutaneous inflammation, epidermal proliferation and differentiation in extensive plaque psoriasis.
    van Pelt JP; de Jong EM; de Bakker ES; van de Kerkhof PC
    Skin Pharmacol Appl Skin Physiol; 1998; 11(2):70-9. PubMed ID: 9603657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
    Gordon KB; Papp KA; Hamilton TK; Walicke PA; Dummer W; Li N; Bresnahan BW; Menter A;
    JAMA; 2003 Dec; 290(23):3073-80. PubMed ID: 14679270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream.
    Alora-Palli MB; Perkins AC; Van Cott A; Kimball AB
    Am J Clin Dermatol; 2010; 11(4):275-83. PubMed ID: 20513160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blind, placebo-controlled, randomized, right-left study comparing calcipotriol monotherapy with a combined treatment of calcipotriol and diflucortolone valerate in chronic plaque psoriasis.
    Salmhofer W; Maier H; Soyer HP; Hönigsmann H; Hödl S
    Acta Derm Venereol Suppl (Stockh); 2000; (211):5-8. PubMed ID: 11234559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of scalp psoriasis. An effective and safe tacalcitol emulsion].
    Ruzicka T; Trompke C
    Hautarzt; 2004 Feb; 55(2):165-70. PubMed ID: 14968327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study.
    Bhushan M; Burden AD; McElhone K; James R; Vanhoutte FP; Griffiths CE
    Br J Dermatol; 2001 Oct; 145(4):546-53. PubMed ID: 11703279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and biochemical effects of an oral leukotriene biosynthesis inhibitor (MK886) in psoriasis.
    de Jong EM; van Vlijmen IM; Scholte JC; Buntinx A; Friedman B; Tanaka W; van de Kerkhof PC
    Skin Pharmacol; 1991; 4(4):278-85. PubMed ID: 1724166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis.
    Strober BE; Crowley JJ; Yamauchi PS; Olds M; Williams DA
    Br J Dermatol; 2011 Sep; 165(3):661-8. PubMed ID: 21574984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: a randomized controlled trial of supervised treatment of psoriasis vulgaris in a day-care setting.
    van de Kerkhof PC; van der Valk PG; Swinkels OQ; Kucharekova M; de Rie MA; de Vries HJ; Damstra R; Oranje AP; de Waard-van der Spek FB; van Neer P; Lijnen RL; Kunkeler AC; van Hees C; Haertlein NG; Hol CW
    Br J Dermatol; 2006 Oct; 155(4):800-7. PubMed ID: 16965431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy of calcipotriol (MC903) cream and betamethasone 17-valerate cream in the treatment of chronic plaque psoriasis. A randomized, double-blind, parallel group multicentre study. Calcipotriol Study Group.
    Molin L; Cutler TP; Helander I; Nyfors B; Downes N
    Br J Dermatol; 1997 Jan; 136(1):89-93. PubMed ID: 9039301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical R-85355, a potent and selective 5-lipoxygenase inhibitor, fails to improve psoriasis.
    van de Kerkhof PC; van Pelt H; Lucker GP; Steijlen PM; Heremans A
    Skin Pharmacol; 1996; 9(5):307-11. PubMed ID: 8990505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of leukotriene B4-induced CD11B/CD18 (Mac-1) expression by BIIL 284, a new long acting LTB4 receptor antagonist, in patients with rheumatoid arthritis.
    Alten R; Gromnica-Ihle E; Pohl C; Emmerich J; Steffgen J; Roscher R; Sigmund R; Schmolke B; Steinmann G
    Ann Rheum Dis; 2004 Feb; 63(2):170-6. PubMed ID: 14722206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
    Reich K; Papp KA; Blauvelt A; Tyring SK; Sinclair R; Thaçi D; Nograles K; Mehta A; Cichanowitz N; Li Q; Liu K; La Rosa C; Green S; Kimball AB
    Lancet; 2017 Jul; 390(10091):276-288. PubMed ID: 28596043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.